Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2000

View Archived Issues

Case studies reveal that gabapentin reduces the frequency of hot flashes

Pilot trial of IL-10 demonstrates improvement in liver histology in chronic HCV patients

(S)-Oxybutynin phase II trial successfully completed

FDA approves Apligraf for diabetic foot ulcers

Celgene and NCI to enter into cooperative R&D agreement for IMiDs

Novavax to begin phase I trial of Androsorb testosterone replacement therapy for women

Corvas completes enrollment for rNAPc2 phase II study

Extended-release venlafaxine proven safe and effective for the treatment of GAD

Applied Molecular Evolution creates anti-RSV monoclonal antibodies

Antibacterial efficacy results of Demegen peptide compound presented

Collaboration to develop CpG DNA-based cancer products

AVI BioPharma and DepoMed explore oral delivery of AVI's antisense agents

Taiwan researchers patent AT1 receptor antagonists with potential in cardiovascular conditions

PNU-190192 and related indolylpyrrolidinemethylpyrrole derivatives as immunosuppressants

Potent tricyclic protein farnesyltransferase inhibitors described by Schering-Plough

Structurally novel compounds synthesized at Leo exert potent insulinotropic activity

Peptide inhibitors of procollagen C-proteinase useful for fibrotic disorders

Agents for herpesvirus infections in development at Boehringer Ingelheim

Novel neuroprotective compounds exert NMDA-activating, AMPA-inhibiting effects

New phospholipase A2 inhibitors presented by Elan in patent literature

Triangle updates development status of clevudine

Japanese team designs new type of anti-HIV prodrug comprising a protease inhibitor and RT inhibitor

LM-1507.Na -- a potent and selective Cys-LT1 receptor antagonist with oral activity

Liposomal formulation of PGE1 prodrug shows promise in peripheral arterial occlusive disease

Nature article reports new anti-TB compound with unique properties

Marimastat does not meet primary or secondary endpoints in brain cancer trial

First clinical results reported for TS-943, a new small-molecule antiplatelet agent

Additive or synergistic effects of surfactant and PDE4 inhibitor in acute lung injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.